AZD5055

DRUG3 trials

Sponsors

AstraZeneca

Conditions

Healthy ParticipantsHealthy SubjectsIdiopathic Pulmonary Fibrosis

Phase 1

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

CompletedNCT05134727

AstraZenecaIdiopathic Pulmonary Fibrosis

Start: 2021-11-18End: 2023-03-31Updated: 2024-05-16

A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.

TerminatedNCT05644600

AstraZenecaHealthy Subjects

Start: 2023-05-26End: 2023-07-17Updated: 2024-02-08

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

CompletedNCT05955183

AstraZenecaHealthy Participants

Start: 2023-07-27End: 2023-12-04Updated: 2023-12-08